|Title:||New-Onset Atrial Fibrillation in Patients With Primary Aldosteronism Receiving Different Treatment Strategies: Systematic Review and Pooled Analysis of Three Studies||Authors:||Tsai, Cheng-Hsuan
|Keywords:||adrenalectomy; atrial fibrillation; hyperaldosteronism; mineralocorticoid receptor antagonist; primary aldosteronism;adrenalectomy; atrial fibrillation; hyperaldosteronism; mineralocorticoid receptor antagonist; primary aldosteronism||Issue Date:||2021||Journal Volume:||12||Source:||Frontiers in endocrinology||Abstract:||
Primary aldosteronism (PA) is a common cause of secondary hypertension and associated with higher incidence of new-onset atrial fibrillation (NOAF). However, the effects of surgical or medical therapies on preventing NOAF in PA patents remain unclear. The aim of this meta-analysis study was to assess the risk of NOAF among PA patients receiving mineralocorticoid receptor antagonist (MRA) treatment, PA patients receiving adrenalectomy, and patients with essential hypertension.
|URI:||https://scholars.lib.ntu.edu.tw/handle/123456789/586864||ISSN:||1664-2392||DOI:||10.3389/fendo.2021.646933||metadata.dc.subject.other:||mineralocorticoid antagonist; adrenalectomy; cerebrovascular accident; congestive heart failure; essential hypertension; follow up; heart arrhythmia; heart infarction; human; hyperthyroidism; incidence; meta analysis; mitral valve disease; new-onset atrial fibrillation; observational study; primary hyperaldosteronism; prospective study; randomized controlled trial (topic); retrospective study; Review; risk factor; systematic review
|Appears in Collections:||法醫學科所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.